PushButton AI Team ·
Big pharma isn't buying AI tools. They're forming partnerships with AI specialists who already know their domain. That distinction matters more than any software demo you'll sit through this month.
Big pharma isn't buying AI tools. They're forming partnerships with AI specialists who already know their domain.
That distinction matters more than any software demo you'll sit through this month.
You're not alone if you've got a $200/month AI subscription collecting digital dust. Most business owners do. Not because you made a bad decision — because you were sold a tool when what you actually needed was a strategy tied to a specific problem.
Here's what Biomunex got right: they didn't just "add AI." They identified two distinct partners for two distinct challenges — discovery and development. Separate problems, separate specialists. That's it.
The lesson isn't about biotech. It's about this: AI works when it's matched to one defined problem, not deployed as a general fix for everything.
Start there. Pick one repetitive task your team does every week that eats two or more hours. Just one. That's your first AI target — not your whole operation, not your CRM, not your hiring process. One task.
Solve that. Measure it. Then move to the next.
What's the one AI tool or subscription you're paying for right now that your team has quietly stopped using?
#AIStrategy #SmallBusiness #AIImplementation #BusinessGrowth
Collaborations with Gordion Bioscience and Tangramed Biotech, two AI-specialized companies, further strengthen Biomunex's integration of ...